After I completed my PhD in Computational Chemistry at the University of Lund and postdoctoral research at the University of Cambridge and the Czech Academy of Sciences, I joined AstraZeneca in 2004. I currently lead the Discovery Sciences Computational Chemistry team within the IMED Biotech Unit, providing computational solutions for drug discovery.
I am passionate about pushing the boundaries of using artificial intelligence and machine learning in drug discovery. A key focus for me has been on building both the team within IMED and collaborating with external experts to advance innovation in drug design and synthesis.
Through a pioneering collaboration with the University of Muenster, my team demonstrated the first application of recurrent Neural Networks to molecular design which has been published in two recent, highly-cited articles. This methodology allows us to design novel drug molecules using machine learning to navigate the breadth of chemical space and to exploit our vast knowledge base.
I am fascinated by applying the latest artificial intelligence and machine learning technologies to drug discovery. It has the potential, together with further progress in automation, to transform the drug discovery process.
Key speaker on Artificial Intelligence in drug discovery at ELRIG Drug Discovery 2018
Key speaker at RSC-BMCS / RSC-CICAG Artificial Intelligence in Chemistry